Calcitonin gene-related peptide monoclonal antibody

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Revision as of 00:50, October 12, 2021 by Notjusttired (talk | contribs) (create)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Calcitonin gene-related peptide monoclonal antibodies (mAbs) or CGRP mAbs are a new type of preventative migraine treatment.[1][2]

Unlike known the small molecule CGRP antagonists known as gepants, CGRP mAbs are used for preventation rather than treatment of an existing migraine.[2][3]

Drugs[edit | edit source]

Currently FDA-licensed CGRP mAbs are:

  • Eptinezumab (Vyepti), approved in 2020
  • Erenumab (Aimovig), approved in 2018
  • Fremanezumab (Ajovy), approved in 2018
  • Galcanezumab (Emgality), approved in 2018[2]

News and articles[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ https://migrainetrust.org/live-with-migraine/healthcare/treatments/calcitonin-gene-related-peptide-monoclonal-antibodies/
  2. ↑ 2.0 2.1 2.2 https://www.drugs.com/medical-answers/new-drugs-treatment-prevention-migraine-3515053/
  3. ↑ https://pubmed.ncbi.nlm.nih.gov/31081399/

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

antibodies Antibody/immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

antagonist A chemical that reduces or helps block the activity of another chemical in the body. For example, most antihistamines are H1 antagonists because they block the H1 histamine receptor, which helps relieve allergy symptoms. The opposite of an agonist.

Retrieved from "https://me-pedia.org/w/index.php?title=Calcitonin_gene-related_peptide_monoclonal_antibody&oldid=93250"